MapLight Therapeutics (MPLT) Corporate Presentation summary

Strategic vision and platform

• Focused on improving outcomes for patients with CNS disorders using a circuit-driven discovery engine and diversified pipeline.

• Discovery platform identifies and validates novel drug targets causally linked to disease symptoms.

• Led by experts in neuropsychiatry and CNS drug development.

• Strong financial position with approximately $450M in cash and runway through 2027.

Pipeline and clinical programs

• Advancing a broad pipeline including ML-007C-MA for schizophrenia and Alzheimer's disease psychosis (ADP), ML-004 for autism spectrum disorder (ASD), and other candidates for Parkinson's and hyperactivity/impulsivity.

• Phase 2 topline results for ML-007C-MA in schizophrenia and ML-004 in ASD expected in Q3 2026; ADP results expected in 2H 2027.

• Ongoing studies leverage a circuit-based discovery platform for pipeline expansion.

ML-007C-MA: Lead asset profile

• Novel M₁/M4 muscarinic agonist co-formulated with a peripheral antagonist, designed for robust activation and improved safety/tolerability.

• Demonstrated strong in vitro and in vivo activity, with potential for comprehensive symptom improvement across positive, negative, and cognitive domains.

• Phase 1 studies showed mostly mild and transient adverse events, low rates of vomiting and anticholinergic effects, and no severe or serious events.

• Dosing is convenient (QD/BID), with minimal titration and no fasting requirements.